D
Range Impact, Inc.
RNGE
$0.1623
$0.01238.20%
D
Sell
11/21/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D- from D+ on 11/21/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0121 to -$0.0517, net income declined 301.43% from -$1.23M to -$4.92M, and total capital declined 46.34% from $17.2M to $9.23M.
Range Impact, Inc. (RNGE) was downgraded to D- from D+ on 11/21/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from -$0.0121 to -$0.0517, net income declined 301.43% from -$1.23M to -$4.92M, and total capital declined 46.34% from $17.2M to $9.23M.
D
Sell
10/7/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 10/7/2024 due to a decline in the volatility index and total return index.
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 10/7/2024 due to a decline in the volatility index and total return index.
C
Hold
8/19/2024Upgraded
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 8/19/2024 due to a major increase in the efficiency index, growth index and solvency index. Operating cash flow increased 50.54% from -$1.11M to -$550.5, and debt to equity declined from 1.13 to 1.1.
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 8/19/2024 due to a major increase in the efficiency index, growth index and solvency index. Operating cash flow increased 50.54% from -$1.11M to -$550.5, and debt to equity declined from 1.13 to 1.1.
D
Sell
4/11/2024Downgrade
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 4/11/2024 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 143.18% from $1.47M to -$636.1, net income declined 102.44% from $3.4M to -$83, and earnings per share declined from $0.0408 to -$0.0009.
Range Impact, Inc. (RNGE) was downgraded to D+ from C- on 4/11/2024 due to a significant decline in the growth index, valuation index and efficiency index. Operating cash flow declined 143.18% from $1.47M to -$636.1, net income declined 102.44% from $3.4M to -$83, and earnings per share declined from $0.0408 to -$0.0009.
C
Hold
12/20/2023Upgraded
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 12/20/2023 due to an increase in the total return index and volatility index.
Range Impact, Inc. (RNGE) was upgraded to C- from D+ on 12/20/2023 due to an increase in the total return index and volatility index.
D
Sell
12/5/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D+ from C- on 12/5/2023 due to a decline in the total return index.
Malachite Innovations, Inc. (MLCT) was downgraded to D+ from C- on 12/5/2023 due to a decline in the total return index.
C
Hold
11/20/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to C- from D- on 11/20/2023 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 9,150.54% from $36.8 to $3.4M, and total capital increased 100.39% from $8.94M to $17.92M.
Malachite Innovations, Inc. (MLCT) was upgraded to C- from D- on 11/20/2023 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 9,150.54% from $36.8 to $3.4M, and total capital increased 100.39% from $8.94M to $17.92M.
D
Sell
9/1/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 9/1/2023 due to an increase in the volatility index and total return index.
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 9/1/2023 due to an increase in the volatility index and total return index.
E
Sell
8/17/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 8/17/2023 due to a decline in the total return index, volatility index and valuation index.
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 8/17/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
8/2/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 8/2/2023 due to a significant increase in the growth index, volatility index and valuation index. EBIT increased 155.57% from -$183.2 to $101.8, earnings per share increased from -$0.0029 to $0.0005, and total revenue increased 32.62% from $3.01M to $4M.
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 8/2/2023 due to a significant increase in the growth index, volatility index and valuation index. EBIT increased 155.57% from -$183.2 to $101.8, earnings per share increased from -$0.0029 to $0.0005, and total revenue increased 32.62% from $3.01M to $4M.
E
Sell
7/24/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index and total return index.
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 7/24/2023 due to a decline in the volatility index and total return index.
D
Sell
7/5/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 7/5/2023 due to an increase in the volatility index and valuation index.
Malachite Innovations, Inc. (MLCT) was upgraded to D- from E+ on 7/5/2023 due to an increase in the volatility index and valuation index.
E
Sell
6/20/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 6/20/2023 due to a substantial decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0008 to -$0.0029, and EBIT declined 225.98% from -$56.2 to -$183.2.
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D- on 6/20/2023 due to a substantial decline in the growth index, volatility index and valuation index. Earnings per share declined from -$0.0008 to -$0.0029, and EBIT declined 225.98% from -$56.2 to -$183.2.
D
Sell
3/14/2023Downgrade
Range Impact, Inc. (RNGE) was downgraded to D- from D on 03/14/2023.
Range Impact, Inc. (RNGE) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and total return index.
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index and total return index.
D
Sell
5/31/2022Upgraded
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
Malachite Innovations, Inc. (MLCT) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 5/13/2022 due to a major decline in the solvency index, growth index and total return index. The quick ratio declined from 0.37 to 0.05, and operating cash flow declined 2.92% from -$383 to -$394.2.
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 5/13/2022 due to a major decline in the solvency index, growth index and total return index. The quick ratio declined from 0.37 to 0.05, and operating cash flow declined 2.92% from -$383 to -$394.2.
D
Sell
5/5/2022Upgraded
Range Impact, Inc. (RNGE) was upgraded to D from D- on 05/05/2022.
Range Impact, Inc. (RNGE) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 4/20/2022 due to a major decline in the solvency index and total return index. The quick ratio declined from 9.61 to 0.37.
Malachite Innovations, Inc. (MLCT) was downgraded to D- from D on 4/20/2022 due to a major decline in the solvency index and total return index. The quick ratio declined from 9.61 to 0.37.
D
Sell
11/9/2021Upgraded
Range Impact, Inc. (RNGE) was upgraded to D from E+ on 11/09/2021.
Range Impact, Inc. (RNGE) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0071 to -$0.0121, and operating cash flow declined 0.97% from -$557.3 to -$562.7.
Malachite Innovations, Inc. (MLCT) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index and growth index. Earnings per share declined from -$0.0071 to -$0.0121, and operating cash flow declined 0.97% from -$557.3 to -$562.7.
D
Sell
8/6/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 8/6/2020 due to an increase in the volatility index and total return index.
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 8/6/2020 due to an increase in the volatility index and total return index.
D
Sell
7/22/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/22/2020 due to a decline in the valuation index and volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/22/2020 due to a decline in the valuation index and volatility index.
D
Sell
7/1/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 7/1/2020 due to an increase in the volatility index.
Vitality Biopharma, Inc. (VBIO) was upgraded to D from D- on 7/1/2020 due to an increase in the volatility index.
D
Sell
6/30/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 6/30/2020 due to a major increase in the growth index, volatility index and total return index. Operating cash flow increased 12.44% from -$835.1 to -$731.2, earnings per share increased from -$0.0156 to -$0.0148, and EBIT increased 2% from -$748.8 to -$733.8.
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 6/30/2020 due to a major increase in the growth index, volatility index and total return index. Operating cash flow increased 12.44% from -$835.1 to -$731.2, earnings per share increased from -$0.0156 to -$0.0148, and EBIT increased 2% from -$748.8 to -$733.8.
E
Sell
5/13/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 5/13/2020 due to a noticeable decline in the efficiency index and volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 5/13/2020 due to a noticeable decline in the efficiency index and volatility index.
D
Sell
4/28/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 4/28/2020 due to an increase in the volatility index.
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 4/28/2020 due to an increase in the volatility index.
E
Sell
4/13/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 4/13/2020 due to a decline in the volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 4/13/2020 due to a decline in the volatility index.
D
Sell
3/23/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index.
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 3/23/2020 due to an increase in the volatility index.
E
Sell
3/6/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 3/6/2020 due to a decline in the volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 3/6/2020 due to a decline in the volatility index.
D
Sell
2/18/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 2/18/2020 due to an increase in the growth index. Earnings per share increased from -$0.0235 to -$0.0156, and EBIT increased 26.69% from -$1.02M to -$748.8.
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 2/18/2020 due to an increase in the growth index. Earnings per share increased from -$0.0235 to -$0.0156, and EBIT increased 26.69% from -$1.02M to -$748.8.
E
Sell
2/4/2020Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 2/4/2020 due to a decline in the growth index and volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 2/4/2020 due to a decline in the growth index and volatility index.
D
Sell
1/10/2020Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 1/10/2020 due to an increase in the growth index and volatility index.
Vitality Biopharma, Inc. (VBIO) was upgraded to D- from E+ on 1/10/2020 due to an increase in the growth index and volatility index.
E
Sell
12/26/2019Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 12/26/2019 due to a large decline in the solvency index, growth index and volatility index. Debt to equity increased from 0.03 to 0.05, and the quick ratio declined from 4.08 to 2.51.
Vitality Biopharma, Inc. (VBIO) was downgraded to E+ from D- on 12/26/2019 due to a large decline in the solvency index, growth index and volatility index. Debt to equity increased from 0.03 to 0.05, and the quick ratio declined from 4.08 to 2.51.
D
Sell
7/16/2019Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/16/2019 due to a significant decline in the total return index, efficiency index and volatility index. Net income declined 690.75% from -$1.21M to -$9.56M, and total capital declined 68.36% from $15.87M to $5.02M.
Vitality Biopharma, Inc. (VBIO) was downgraded to D- from D on 7/16/2019 due to a significant decline in the total return index, efficiency index and volatility index. Net income declined 690.75% from -$1.21M to -$9.56M, and total capital declined 68.36% from $15.87M to $5.02M.
D
Sell
11/15/2018Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/15/2018 due to a significant decline in the efficiency index and solvency index. Net income declined 7.54% from -$1.14M to -$1.22M.
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/15/2018 due to a significant decline in the efficiency index and solvency index. Net income declined 7.54% from -$1.14M to -$1.22M.
C
Hold
8/16/2018Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 8/16/2018 due to a significant increase in the efficiency index, solvency index and valuation index.
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 8/16/2018 due to a significant increase in the efficiency index, solvency index and valuation index.
D
Sell
11/16/2017Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from D+ on 11/16/2017 due to a significant decline in the efficiency index, valuation index and volatility index.
Vitality Biopharma, Inc. (VBIO) was downgraded to D from D+ on 11/16/2017 due to a significant decline in the efficiency index, valuation index and volatility index.
D
Sell
8/11/2017Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 8/11/2017 due to a significant increase in the efficiency index, valuation index and solvency index. Net income increased 0.69% from -$1.11M to -$1.11M.
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 8/11/2017 due to a significant increase in the efficiency index, valuation index and solvency index. Net income increased 0.69% from -$1.11M to -$1.11M.
D
Sell
6/29/2017Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 6/29/2017 due to a significant decline in the efficiency index, valuation index and growth index. Operating cash flow declined 64.4% from -$304.8 to -$501.1, EBIT declined 47.76% from -$912.1 to -$1.35M, and total revenue declined 20.91% from $39.7 to $31.4.
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 6/29/2017 due to a significant decline in the efficiency index, valuation index and growth index. Operating cash flow declined 64.4% from -$304.8 to -$501.1, EBIT declined 47.76% from -$912.1 to -$1.35M, and total revenue declined 20.91% from $39.7 to $31.4.
C
Hold
2/16/2017Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 2/16/2017 due to a significant increase in the efficiency index, total return index and volatility index. Total capital increased 26% from -$920.5 to -$681.2.
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D on 2/16/2017 due to a significant increase in the efficiency index, total return index and volatility index. Total capital increased 26% from -$920.5 to -$681.2.
D
Sell
11/18/2016Downgrade
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/18/2016 due to a significant decline in the efficiency index, growth index and solvency index. Net income declined 160.92% from -$439.4 to -$1.15M, earnings per share declined from -$0.0436 to -$0.0936, and EBIT declined 93.11% from -$423.8 to -$818.4.
Vitality Biopharma, Inc. (VBIO) was downgraded to D from C- on 11/18/2016 due to a significant decline in the efficiency index, growth index and solvency index. Net income declined 160.92% from -$439.4 to -$1.15M, earnings per share declined from -$0.0436 to -$0.0936, and EBIT declined 93.11% from -$423.8 to -$818.4.
C
Hold
10/19/2016Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D+ on 10/19/2016 due to an increase in the total return index and volatility index.
Vitality Biopharma, Inc. (VBIO) was upgraded to C- from D+ on 10/19/2016 due to an increase in the total return index and volatility index.
D
Sell
9/21/2016Upgraded
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 9/21/2016 due to an increase in the total return index, valuation index and growth index. Earnings per share increased from -$0.1187 to -$0.0436, and EBIT increased 14.37% from -$494.9 to -$423.8.
Vitality Biopharma, Inc. (VBIO) was upgraded to D+ from D on 9/21/2016 due to an increase in the total return index, valuation index and growth index. Earnings per share increased from -$0.1187 to -$0.0436, and EBIT increased 14.37% from -$494.9 to -$423.8.
D
Sell
7/1/2016Upgraded
Stevia First Corporation (STVF) was upgraded to D from E+ on 7/1/2016 due to a significant increase in the efficiency index, solvency index and growth index.
Stevia First Corporation (STVF) was upgraded to D from E+ on 7/1/2016 due to a significant increase in the efficiency index, solvency index and growth index.
E
Sell
6/24/2016Downgrade
Stevia First Corporation (STVF) was downgraded to E+ from D on 6/24/2016 due to a significant decline in the solvency index, growth index and efficiency index.
Stevia First Corporation (STVF) was downgraded to E+ from D on 6/24/2016 due to a significant decline in the solvency index, growth index and efficiency index.
D
Sell
3/11/2016Downgrade
Stevia First Corporation (STVF) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
Stevia First Corporation (STVF) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
D
Sell
1/15/2016Downgrade
Stevia First Corporation (STVF) was downgraded to D+ from C- on 1/15/2016 due to a large decline in the total return index.
Stevia First Corporation (STVF) was downgraded to D+ from C- on 1/15/2016 due to a large decline in the total return index.
C
Hold
12/31/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D+ on 12/31/2015 due to a large increase in the total return index and valuation index.
Stevia First Corporation (STVF) was upgraded to C- from D+ on 12/31/2015 due to a large increase in the total return index and valuation index.
D
Sell
11/18/2015Downgrade
Stevia First Corporation (STVF) was downgraded to D+ from C- on 11/18/2015 due to a significant decline in the efficiency index, solvency index and valuation index. Total capital declined 74.17% from -$895.8 to -$231.4.
Stevia First Corporation (STVF) was downgraded to D+ from C- on 11/18/2015 due to a significant decline in the efficiency index, solvency index and valuation index. Total capital declined 74.17% from -$895.8 to -$231.4.
C
Hold
8/17/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 8/17/2015 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.29 to 0.58, and total revenue increased 6.91% from $57.9 to $61.9.
Stevia First Corporation (STVF) was upgraded to C- from D on 8/17/2015 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 0.29 to 0.58, and total revenue increased 6.91% from $57.9 to $61.9.
D
Sell
6/26/2015Downgrade
Stevia First Corporation (STVF) was downgraded to D from C- on 6/26/2015 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 0.67 to 0.29, and net income declined 26.21% from -$1.14M to -$842.7.
Stevia First Corporation (STVF) was downgraded to D from C- on 6/26/2015 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 0.67 to 0.29, and net income declined 26.21% from -$1.14M to -$842.7.
C
Hold
2/18/2015Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 2/18/2015 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 40.95% from -$518.4 to -$730.7.
Stevia First Corporation (STVF) was upgraded to C- from D on 2/18/2015 due to a significant increase in the efficiency index, growth index and volatility index. Operating cash flow increased 40.95% from -$518.4 to -$730.7.
D
Sell
8/15/2014Downgrade
Stevia First Corporation (STVF) was downgraded to D from C- on 8/15/2014 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0223 to -$0.01, net income declined 54.04% from -$1.43M to -$655.8, and the quick ratio declined from 0.91 to 0.58.
Stevia First Corporation (STVF) was downgraded to D from C- on 8/15/2014 due to a significant decline in the efficiency index, growth index and solvency index. Earnings per share declined from -$0.0223 to -$0.01, net income declined 54.04% from -$1.43M to -$655.8, and the quick ratio declined from 0.91 to 0.58.
C
Hold
7/1/2014Upgraded
Stevia First Corporation (STVF) was upgraded to C- from D on 7/1/2014 due to a significant increase in the efficiency index, valuation index and solvency index. Debt to equity declined from 2.15 to 0, and net income increased 36.54% from -$1.05M to -$1.43M.
Stevia First Corporation (STVF) was upgraded to C- from D on 7/1/2014 due to a significant increase in the efficiency index, valuation index and solvency index. Debt to equity declined from 2.15 to 0, and net income increased 36.54% from -$1.05M to -$1.43M.
OTC PK
03/14/2025 3:41PM Eastern
Quotes delayed
